title: Stromal cell derived factor-1 (SDF-1) targeting reperfusion reduces myocardial infarction in isolated rat hearts.
abstract: Recent studies have shown that stromal cell derived factor-1 (SDF-1), first known as a cytokine involved in recruiting stem cells into injured organs, confers myocardial protection in myocardial infarction, which is not dependent on stem cell recruitment but related with modulation of ischemia-reperfusion (I/R) injury. However, the effect of SDF has been studied only in a preischemic exposure model, which is not clinically relevant if SDF is to be used as a therapeutic agent. Our study was aimed at evaluating whether or not SDF-1 confers cardioprotection during the reperfusion period. Hearts from SD rats were isolated and perfused with the Langendorff system. Proximal left coronary artery ligation, reperfusion, and SDF perfusion in KH buffer was done according to study protocol. Area of necrosis (AN) relative to area at risk (AR) was the primary endpoint of the study. Significant reduction of AN/AR by SDF in an almost dose-dependent manner was noted during both the preischemic exposure and reperfusion periods. In particular, infusion of a high concentration of SDF (25 nM/L) resulted in a dramatic reduction of infarct size, which was greater than that achieved with ischemic pre- or postconditioning. SDF perfusion during reperfusion was associated with a similar significant reduction of infarct size as preischemic SDF exposure. Further studies are warranted to assess the potential of SDF as a therapeutic agent for reducing I/R injury in clinical practice.
authors.affiliation: Cardiovascular Research Institute, Research Institute for Convergence of Biomedical Science and Technology, Pusan National University Yangsan Hospital, Yangsan-city, Gyungsangnam-do, Republic of Korea.
authors.forename: Young-Ho
authors.initials: YH
authors.lastname: Jang
authors.forename: June-Hong
authors.initials: JH
authors.lastname: Kim
authors.forename: Changill
authors.initials: C
authors.lastname: Ban
authors.forename: Kyohan
authors.initials: K
authors.lastname: Ahn
authors.forename: Jae-Hun
authors.initials: JH
authors.lastname: Cheong
authors.forename: Hyung-Hoi
authors.initials: HH
authors.lastname: Kim
authors.forename: Jung-Soo
authors.initials: JS
authors.lastname: Kim
authors.forename: Yong-Hyun
authors.initials: YH
authors.lastname: Park
authors.forename: Jun
authors.initials: J
authors.lastname: Kim
authors.forename: Kook-Jin
authors.initials: KJ
authors.lastname: Chun
authors.forename: Gyeong-Ho
authors.initials: GH
authors.lastname: Lee
authors.forename: Miju
authors.initials: M
authors.lastname: Kim
authors.forename: Cheolmin
authors.initials: C
authors.lastname: Kim
authors.forename: Zhelong
authors.initials: Z
authors.lastname: Xu
mesh_terms: D000818:Animals; D015153:Blotting, Western; D002316:Cardiotonic Agents / Q000627:therapeutic use*; D054377:Chemokine CXCL12 / Q000235:genetics / Q000627:therapeutic use*; D002633:Chemotaxis / Q000187:drug effects; D004305:Dose-Response Relationship, Drug; D048049:Extracellular Signal-Regulated MAP Kinases / Q000378:metabolism / Q000502:physiology; D006321:Heart / Q000187:drug effects*; D006334:Heart Function Tests; D066298:In Vitro Techniques; D008297:Male; D009203:Myocardial Infarction / Q000473:pathology / Q000517:prevention & control*; D015428:Myocardial Reperfusion Injury / Q000473:pathology / Q000517:prevention & control*; D009206:Myocardium / Q000473:pathology; D009336:Necrosis; D051381:Rats; D017207:Rats, Sprague-Dawley; D011994:Recombinant Proteins / Q000627:therapeutic use
chemical_list: D002316:Cardiotonic Agents; D054377:Chemokine CXCL12; D011994:Recombinant Proteins; D048049:Extracellular Signal-Regulated MAP Kinases